AbbVie (ABBV) announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.Vyalev is a solution of carbidopa (CD) and levodopa (LD) prodrugs, which are the standard of care for PD patients. Prodrugs are medications that become active once they enter the body. The drug has been designed to offer continuous subcutaneous delivery of CD/LD prodrugs throug ...